Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) and INSYS Therapeutics Inc. (NASDAQ:INSY) compete against each other in the Biotechnology sector. We will compare them and contrast their risk, analyst recommendations, institutional ownership, profitability, dividends, earnings and valuation.
Valuation and Earnings
Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Zynerba Pharmaceuticals Inc. and INSYS Therapeutics Inc.
Table 2 has Zynerba Pharmaceuticals Inc. and INSYS Therapeutics Inc.’s net margins, return on assets and return on equity.
Zynerba Pharmaceuticals Inc.’s current beta is 4.93 and it happens to be 393.00% more volatile than Standard Poor’s 500. Competitively, INSYS Therapeutics Inc. is 156.00% more volatile than Standard Poor’s 500, because of the 2.56 beta.
Zynerba Pharmaceuticals Inc.’s Current Ratio is 8 while its Quick Ratio is 8. On the competitive side is, INSYS Therapeutics Inc.